Why Novartis Is Still A 'Buy' After 15% Surge

Novartis (NVS) shares have surged over 15% to a new historic peak, propelled by strong performance across its cardiovascular, oncology, and immunology franchises, including Cosentyx sales of $1.53 billion in the first three months of 2025, up 15.7% year-over-year. This upward trajectory continues despite broader pharmaceutical industry pressures, further supported by recent regulatory successes like Swissmedic's approval of Coartem Baby for infant malaria.

Analysis

Novartis (NVS) has demonstrated significant market outperformance, with its stock price appreciating by over 15% to reach a new historic peak. This upward momentum is fundamentally driven by robust performance within its key franchises, namely cardiovascular, oncology, and immunology. A primary contributor to this strength is the blockbuster drug Cosentyx, which generated sales of $1.53 billion in the first three months of 2025, marking a 15.7% increase year-over-year and underscoring strong commercial execution. Further bolstering the positive outlook, Novartis recently secured regulatory approval from Swissmedic for Coartem Baby, a first-of-its-kind treatment for malaria in infants, highlighting successful pipeline development. Notably, this bullish trend persists despite stated political pressures on the pharmaceutical sector, indicating that investors are currently prioritizing the company's strong operational results and growth catalysts over broader industry risks.

Key Decisions for Investors

• Given the stock's powerful momentum and strong fundamental drivers, investors may consider holding or adding to long positions, as the combination of revenue growth and pipeline success supports the current valuation.
• Investors should closely monitor the continued sales trajectory of key products like Cosentyx and the commercial rollout of new approvals like Coartem Baby, as these are the primary justifications for the ongoing bullish sentiment.
• While the company's performance is strong, it is prudent to remain aware of the referenced political and trade-related risks to the pharmaceutical sector, as any materialization of these headwinds could temper the stock's upward trend.